Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
USPs of Cardiovascular API
- Well-controlled impurity profile (APIs meets current and future stringent impurity limits).
- Improved API flow property through controlled crystallization and process modifications to ease formulation development.
- Completely backward integrated on the KSMs to ensure uninterrupted supplies.
- Robust and sustainable supply chain.
- Eligible to file DMF’s globally in all the markets.
- Comprehensive assessment of synthetic routes and all toxicological attributes.
- All GTIs are controlled below TTC limits.
- Robust advanced analytical techniques to detect potential nitrosamine impurities.
- Process development through QBD approach.
- Customized particle sizes (PSD) to meet formulation requirements.
- Successful BE/dossier filing record of accomplishment in the markets.
- Multiple synthetic steps manufactured in-house.
- API and KSM process with no IP Issues.
- Comprehensive assessment of synthetic routes and all toxicological attributes.
Get access to Dr. Reddys largest Cardiovascular API portfolios to support your formulation success.
Dr. Reddy's offers a wide selection of cardiovascular active pharmaceutical ingredients used in the production of formulations to treat cardiovascular diseases. Our portfolio includes a broad class of cardiovascular molecules: HMG–CoA reductase inhibitors (statins), adenosine triphosphate-citrate lyase (ACL) inhibitors, calcium channel blockers, angiotensin II receptor antagonists, anticoagulants, beta-blockers, lipid modifiers, and others.
Dr. Reddy's is well-positioned to meet the global demands of Cardiovascular APIs. As a Cardiovascular API manufacturer and supplier, we follow a multistage synthesis to ensure supply chain sustainability and compliance with global regulatory requirements. In addition, Dr. Reddy's has established solid strategic sourcing, logistics partnerships and works closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.
Look at Dr. Reddy's broad selection of active pharmaceutical ingredients cardiovascular drugs used to treat cardiovascular diseases like hypertension, angina, benign prostate hyperplasia, pulmonary arterial hypertension, heredity angioedema, and many more.
Our portfolio includes a broad class of cardiovascular molecules:
- HMG–CoA reductase inhibitors (statins)
- Adenosine triphosphate-citrate lyase (ACL) inhibitors
- Calcium channel blockers
- Angiotensin II receptor antagonists
- Anticoagulants
- Beta-blockers
- Others
The global cardiovascular drugs market size is projected to hit around USD 231.7 billion by 2030 from valued at USD 155.6 billion in 2021 and growing at a CAGR of 4.52% from 2022 and 2030.
The global cardiovascular drugs market size is projected to hit around USD 231.7 billion by 2030 from valued at USD 155.6 billion in 2021 and growing at a CAGR of 4.52% from 2022 and 2030.
HMG–CoA inhibitors - decrease cholesterol levels. ACL Inhibitors - Direct inhibition of ACL by ETC-1002 lowers cytosolic acetyl CoA. Calcium channel blockers - prevent calcium from entering the cells of the heart & arteries. Angiotensin ii receptor antagonists - help relax veins & arteries to lower BP & make it easier for your heart to pump blood.
A control strategy has been defined using the QbD approach at every synthesis step and ensures that Dr. Reddy's APIs are free from potential genotoxic and carcinogenic impurities
Dr. Reddy's is well-positioned to meet the global demands of Cardiovascular APIs. We follow a multistage synthesis to ensure supply chain sustainability and compliance with global regulatory requirements. We established solid strategic sourcing and logistics partnerships and work closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.
Used to treat or improve symptoms of cardiovascular conditions including high blood pressure and heart failure.
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。